Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Biofrontera AG stock logo
BFRA
Biofrontera
$2.60
$2.95
$2.09
$7.54
$73.73M1.0227,512 shs7,263 shs
Concert Pharmaceuticals, Inc. stock logo
CNCE
Concert Pharmaceuticals
$8.37
$8.37
$2.66
$8.55
$401.26M0.522.97 million shsN/A
ADVANZ PHARMA Corp. Limited stock logo
CXRXF
ADVANZ PHARMA
$17.06
$17.06
$2.13
$18.00
$834.46MN/A11,851 shs39 shs
HOOKIPA Pharma Inc. stock logo
HOOK
HOOKIPA Pharma
$1.27
+2.8%
$1.40
$0.72
$6.77
$14.99M0.8982,873 shs13,921 shs
MEI Pharma, Inc. stock logo
MEIP
MEI Pharma
$2.84
+18.1%
$2.23
$1.46
$4.10
N/A0.1944,443 shs53,769 shs
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Biofrontera AG stock logo
BFRA
Biofrontera
0.00%0.00%0.00%0.00%0.00%
Concert Pharmaceuticals, Inc. stock logo
CNCE
Concert Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
ADVANZ PHARMA Corp. Limited stock logo
CXRXF
ADVANZ PHARMA
0.00%0.00%0.00%0.00%0.00%
HOOKIPA Pharma Inc. stock logo
HOOK
HOOKIPA Pharma
0.00%+1.20%-17.32%+53.33%-78.16%
MEI Pharma, Inc. stock logo
MEIP
MEI Pharma
0.00%+1.25%+31.86%+41.75%+0.53%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Biofrontera AG stock logo
BFRA
Biofrontera
N/AN/AN/AN/AN/AN/AN/AN/A
Concert Pharmaceuticals, Inc. stock logo
CNCE
Concert Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
ADVANZ PHARMA Corp. Limited stock logo
CXRXF
ADVANZ PHARMA
N/AN/AN/AN/AN/AN/AN/AN/A
HOOKIPA Pharma Inc. stock logo
HOOK
HOOKIPA Pharma
2.9716 of 5 stars
3.25.00.00.00.01.70.6
MEI Pharma, Inc. stock logo
MEIP
MEI Pharma
2.541 of 5 stars
0.05.00.04.20.00.81.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Biofrontera AG stock logo
BFRA
Biofrontera
0.00
N/AN/AN/A
Concert Pharmaceuticals, Inc. stock logo
CNCE
Concert Pharmaceuticals
0.00
N/AN/AN/A
ADVANZ PHARMA Corp. Limited stock logo
CXRXF
ADVANZ PHARMA
0.00
N/AN/AN/A
HOOKIPA Pharma Inc. stock logo
HOOK
HOOKIPA Pharma
2.33
Hold$4.50255.73% Upside
MEI Pharma, Inc. stock logo
MEIP
MEI Pharma
2.00
HoldN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Biofrontera AG stock logo
BFRA
Biofrontera
$36.19M2.04N/AN/A$0.35 per share7.43
Concert Pharmaceuticals, Inc. stock logo
CNCE
Concert Pharmaceuticals
$32.58M12.32N/AN/A$3.24 per share2.58
ADVANZ PHARMA Corp. Limited stock logo
CXRXF
ADVANZ PHARMA
$525.58M1.59N/AN/A$0.16 per share106.63
HOOKIPA Pharma Inc. stock logo
HOOK
HOOKIPA Pharma
$43.95M0.35N/AN/A$4.25 per share0.30
MEI Pharma, Inc. stock logo
MEIP
MEI Pharma
$65.30MN/A$6.30 per share0.45$4.96 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Biofrontera AG stock logo
BFRA
Biofrontera
-$14.88M-$0.73N/AN/A-59.44%-93.31%-24.02%N/A
Concert Pharmaceuticals, Inc. stock logo
CNCE
Concert Pharmaceuticals
-$80.05M-$3.21N/AN/AN/AN/A-109.43%-76.65%N/A
ADVANZ PHARMA Corp. Limited stock logo
CXRXF
ADVANZ PHARMA
-$74.86MN/AN/AN/A-15.31%N/A-4.38%N/A
HOOKIPA Pharma Inc. stock logo
HOOK
HOOKIPA Pharma
-$43.50M-$5.85N/AN/AN/A-785.66%-120.09%-77.14%8/6/2025 (Estimated)
MEI Pharma, Inc. stock logo
MEIP
MEI Pharma
$17.78M-$4.75N/AN/AN/AN/A-77.00%-64.79%9/17/2025 (Estimated)

Latest CNCE, CXRXF, BFRA, HOOK, and MEIP Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
HOOKIPA Pharma Inc. stock logo
HOOK
HOOKIPA Pharma
-$0.61-$1.23-$0.62-$1.23$3.38 millionN/A
5/13/2025Q3 2025
MEI Pharma, Inc. stock logo
MEIP
MEI Pharma
N/A-$0.39N/A-$0.39N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Biofrontera AG stock logo
BFRA
Biofrontera
N/AN/AN/AN/AN/A
Concert Pharmaceuticals, Inc. stock logo
CNCE
Concert Pharmaceuticals
N/AN/AN/AN/AN/A
ADVANZ PHARMA Corp. Limited stock logo
CXRXF
ADVANZ PHARMA
N/AN/AN/AN/AN/A
HOOKIPA Pharma Inc. stock logo
HOOK
HOOKIPA Pharma
N/AN/AN/AN/AN/A
MEI Pharma, Inc. stock logo
MEIP
MEI Pharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Biofrontera AG stock logo
BFRA
Biofrontera
0.13
1.26
1.13
Concert Pharmaceuticals, Inc. stock logo
CNCE
Concert Pharmaceuticals
N/A
9.03
9.03
ADVANZ PHARMA Corp. Limited stock logo
CXRXF
ADVANZ PHARMA
257.04
2.39
1.61
HOOKIPA Pharma Inc. stock logo
HOOK
HOOKIPA Pharma
N/A
3.61
3.61
MEI Pharma, Inc. stock logo
MEIP
MEI Pharma
N/A
16.78
16.78

Institutional Ownership

CompanyInstitutional Ownership
Biofrontera AG stock logo
BFRA
Biofrontera
60.07%
Concert Pharmaceuticals, Inc. stock logo
CNCE
Concert Pharmaceuticals
70.63%
ADVANZ PHARMA Corp. Limited stock logo
CXRXF
ADVANZ PHARMA
N/A
HOOKIPA Pharma Inc. stock logo
HOOK
HOOKIPA Pharma
63.88%
MEI Pharma, Inc. stock logo
MEIP
MEI Pharma
52.38%

Insider Ownership

CompanyInsider Ownership
Biofrontera AG stock logo
BFRA
Biofrontera
N/A
Concert Pharmaceuticals, Inc. stock logo
CNCE
Concert Pharmaceuticals
11.33%
ADVANZ PHARMA Corp. Limited stock logo
CXRXF
ADVANZ PHARMA
N/A
HOOKIPA Pharma Inc. stock logo
HOOK
HOOKIPA Pharma
3.30%
MEI Pharma, Inc. stock logo
MEIP
MEI Pharma
3.12%
CompanyEmployeesShares OutstandingFree FloatOptionable
Biofrontera AG stock logo
BFRA
Biofrontera
13828.36 millionN/ANot Optionable
Concert Pharmaceuticals, Inc. stock logo
CNCE
Concert Pharmaceuticals
6447.94 million42.51 millionOptionable
ADVANZ PHARMA Corp. Limited stock logo
CXRXF
ADVANZ PHARMA
42948.91 millionN/ANot Optionable
HOOKIPA Pharma Inc. stock logo
HOOK
HOOKIPA Pharma
5612.19 million11.79 millionOptionable
MEI Pharma, Inc. stock logo
MEIP
MEI Pharma
100N/AN/AOptionable

Recent News About These Companies

MEI Pharma Registered Shs
MEI Pharma (NASDAQ:MEIP) Stock, Option Chain
MEI Pharma gets grant for compounds for treating proliferative diseases
MEI Pharma reviews strategic options amid fiscal changes
MEI Pharma Reports Fiscal Year End 2024 Cash Position
MEI Pharma Reports Fiscal Year End 2024 Cash Position
MEI Pharma To Begin Evaluation Of Strategic Alternatives - Quick Facts
MEI Pharma to Consider Strategic Alternatives

Media Sentiment Over Time

Biofrontera stock logo

Biofrontera NASDAQ:BFRA

Biofrontera AG engages in the development, sale and distribution of dermatological drugs and medical cosmetics for the care, protection and treatment of the skin. Its products include Ameluz, BF-RhodolesXepi and Belixos. The company was founded by Hermann Lübbert in 1997 and is headquartered in Leverkusen, Germany.

Concert Pharmaceuticals stock logo

Concert Pharmaceuticals NASDAQ:CNCE

Concert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system disorders. The company was founded by Richard H. Aldrich, Roger D. Tung and Christoph H. Westphal on April 12, 2006 and is headquartered in Lexington, MA.

ADVANZ PHARMA stock logo

ADVANZ PHARMA OTCMKTS:CXRXF

$17.06 0.00 (0.00%)
As of 06/10/2021

ADVANZ PHARMA Corp. Limited, a pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products worldwide. The company operates through two segments: ADVANZ PHARMA International and ADVANZ PHARMA North America. Its ADVANZ PHARMA International segment offers a portfolio of branded and generic prescription products to wholesalers, distributors, hospitals, and pharmacies. This segment's products include Brinavess for the conversion of onset atrial fibrillation to sinus rhythm in adults; Aggrastat, a reversible GP IIb/IIIa inhibitor indicated for use in patients with acute coronary syndrome; Xydalba, a semi-synthetic lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections in adults; and Zevtera/Mabelio, a cephalosporin antibiotic for the treatment of community-acquired and hospital-acquired pneumonia. The company's ADVANZ PHARMA North America segment provides Donnatal for the treatment of irritable bowel syndrome; Zonegran for the treatment of partial seizures in adults with epilepsy; Nilandron for the treatment of metastatic prostate cancer; Lanoxin for the treatment of mild to moderate heart failure and atrial fibrillation; Plaquenil for the treatment of lupus and rheumatoid arthritis; and Photofrin for the treatment of certain types of cancer. It also offers Prostaglandin E1 formulations for the treatment of erectile dysfunction and peripheral arterial occlusive disease under the Prostavasin, Viridal, Vasaprostan, and Edex brands, as well as holds licensed commercialization rights to a pre-registration drug/device combination product, Trevyent for the treatment of pulmonary arterial hypertension. It sells its products through direct sales and local distribution relationships. The company was formerly known as ADVANZ PHARMA Corp. and changed its name to ADVANZ PHARMA Corp. Limited in December 2019. ADVANZ PHARMA Corp. Limited is headquartered in London, the United Kingdom.

HOOKIPA Pharma stock logo

HOOKIPA Pharma NASDAQ:HOOK

$1.26 +0.04 (+2.85%)
Closing price 07/3/2025 03:13 PM Eastern
Extended Trading
$1.26 0.00 (-0.40%)
As of 07/3/2025 04:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

HOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.

MEI Pharma stock logo

MEI Pharma NASDAQ:MEIP

$2.84 +0.44 (+18.13%)
Closing price 07/3/2025 03:27 PM Eastern
Extended Trading
$2.71 -0.13 (-4.55%)
As of 07/3/2025 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex which has completed Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer. MEI Pharma, Inc. has a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.